WO2010030670A3 - Compositions and methods for the prevention of oxidative degradation of proteins - Google Patents
Compositions and methods for the prevention of oxidative degradation of proteins Download PDFInfo
- Publication number
- WO2010030670A3 WO2010030670A3 PCT/US2009/056365 US2009056365W WO2010030670A3 WO 2010030670 A3 WO2010030670 A3 WO 2010030670A3 US 2009056365 W US2009056365 W US 2009056365W WO 2010030670 A3 WO2010030670 A3 WO 2010030670A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- prevention
- compositions
- methods
- oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0918978A BRPI0918978A2 (en) | 2008-09-10 | 2009-09-09 | compositions and methods the prevention of oxidative degradation of proteins |
EP09792371A EP2334323A2 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
CA2734275A CA2734275A1 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
CN2009801445283A CN102209554A (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
JP2011526940A JP5705115B2 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for prevention of oxidative degradation of proteins |
AU2009291865A AU2009291865A1 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
MX2011002372A MX2011002372A (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins. |
IL211234A IL211234A0 (en) | 2008-09-10 | 2011-02-15 | Compositions and methods for the prevention of oxidative degradation of proteins |
IL229180A IL229180A0 (en) | 2008-09-10 | 2013-10-31 | Compositions and methods for the prevention of oxidative degradation of proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9587808P | 2008-09-10 | 2008-09-10 | |
US61/095,878 | 2008-09-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12178248.6A Previously-Filed-Application EP2684570A1 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010030670A2 WO2010030670A2 (en) | 2010-03-18 |
WO2010030670A3 true WO2010030670A3 (en) | 2010-05-06 |
Family
ID=41351722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/056365 WO2010030670A2 (en) | 2008-09-10 | 2009-09-09 | Compositions and methods for the prevention of oxidative degradation of proteins |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100068210A1 (en) |
EP (2) | EP2684570A1 (en) |
JP (2) | JP5705115B2 (en) |
KR (1) | KR20110076918A (en) |
CN (2) | CN102209554A (en) |
AU (1) | AU2009291865A1 (en) |
BR (1) | BRPI0918978A2 (en) |
CA (1) | CA2734275A1 (en) |
IL (2) | IL211234A0 (en) |
MX (1) | MX2011002372A (en) |
WO (1) | WO2010030670A2 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101939557B1 (en) | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | Combination of an insulin and a GLP-1 agonist |
PT3345593T (en) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
CN107308442B (en) | 2009-11-13 | 2022-10-18 | 赛诺菲-安万特德国有限公司 | Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine |
EP2364690A1 (en) * | 2010-02-12 | 2011-09-14 | Centro De Ingenieria Genetica Y Biotecnologia | Orally administrable pharmaceutical pellet of epidermal growth factor |
BR112012021873B8 (en) * | 2010-03-22 | 2021-09-14 | Genentech Inc | composition of matter, article of manufacture, methods for preparing a composition, for increasing the stability of a protein in polysorbate-free aqueous solution and for preventing or reducing aggregation of a protein in polysorbate-free aqueous solution |
LT2611458T (en) | 2010-08-30 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
KR101913874B1 (en) * | 2010-11-10 | 2018-10-31 | 인리젠 | Injectable formulations for organ augmentation |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US20140088014A1 (en) | 2011-06-07 | 2014-03-27 | Asahi Kasei Pharma Corporation | Freeze-dried preparation containing high-purity pth and method for producing same |
MX370264B (en) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients. |
AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
ES2693508T3 (en) * | 2011-10-26 | 2018-12-12 | Amgen Inc. | Methods to reduce or eliminate protein modification and degradation due to exposure to UV light |
TWI641381B (en) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
WO2014160495A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Formulations with reduced oxidation |
US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
WO2014160371A1 (en) * | 2013-03-13 | 2014-10-02 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
US20140314778A1 (en) * | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
CA2904169C (en) * | 2013-03-13 | 2021-12-07 | Genentech, Inc. | Formulations with reduced oxidation |
KR102202476B1 (en) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | Cell culture media and methods of antibody production |
BR112016013832A2 (en) | 2014-01-09 | 2017-08-08 | Sanofi Sa | USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE |
EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
JP6735674B2 (en) | 2014-01-09 | 2020-08-05 | サノフイSanofi | Stabilized pharmaceutical formulation of insulin aspart |
SI3229828T1 (en) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
WO2017049205A2 (en) * | 2015-09-18 | 2017-03-23 | Amunix Operating Inc. | Growth hormone formulation |
JP6703098B2 (en) | 2016-03-31 | 2020-06-03 | 富士フイルム株式会社 | Semiconductor manufacturing treatment liquid and pattern forming method |
US11142553B2 (en) | 2016-11-29 | 2021-10-12 | Spiber Inc. | Protein composition, method for producing same and method for improving heat stability |
MA50266A (en) * | 2017-09-22 | 2020-07-29 | Immunogen Inc | METHODS FOR PREVENTING THE OXIDATION OF METHIONINE IN IMMUNOCONJUGATES |
JP6577683B2 (en) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | Liquid pharmaceutical composition containing teriparatide having excellent stability |
JP2019156805A (en) * | 2018-03-16 | 2019-09-19 | ナガセ医薬品株式会社 | Container filling human pth(1-34) liquid pharmaceutical composition, and method for manufacturing the same |
CA3107077A1 (en) * | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
TW202019478A (en) | 2018-08-08 | 2020-06-01 | 美商建南德克公司 | Use of tryptophan derivatives and L-methionine for protein formulation |
JP2020052012A (en) * | 2018-09-28 | 2020-04-02 | 株式会社Lsiメディエンス | Immunoassay reagent using insoluble carrier |
CN112451652A (en) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | Recombinant human thyrotropin injection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1197221A1 (en) * | 1999-03-01 | 2002-04-17 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
EP1260230A1 (en) * | 2000-02-29 | 2002-11-27 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
US5849700A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5714338A (en) | 1993-12-10 | 1998-02-03 | Genentech, Inc. | Methods for diagnosis of allergy |
MX9602818A (en) | 1994-01-18 | 1997-06-28 | Genentech Inc | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS. |
WO1995023865A1 (en) | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
EP1297847A3 (en) | 1996-01-23 | 2003-05-07 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
DK0941344T3 (en) | 1996-11-27 | 2004-09-27 | Genentech Inc | Humanized anti-CD11a antibodies |
DE69829891T2 (en) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF antibody |
DE69838249T3 (en) | 1997-05-15 | 2012-01-19 | Genentech, Inc. | ANTI-APO-2 ANTIBODIES |
JP5149470B2 (en) * | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | Novel factor VIII formulation without albumin |
JP3062493B1 (en) * | 1999-03-19 | 2000-07-10 | 明治乳業株式会社 | Bifidus factor photodegradation inhibitor |
CH694589A5 (en) | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies. |
AU778199B2 (en) | 1999-10-29 | 2004-11-25 | Genentech Inc. | Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
US6989138B2 (en) * | 2000-10-24 | 2006-01-24 | Diatide, Inc. | Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans |
ATE355087T1 (en) * | 2000-10-24 | 2006-03-15 | Cis Bio Int | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS WITH A HYDROPHILIC THIOETHER OR A HYDROPHILIC 6-HYDROXY-CHROMANE |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
EP1507793A4 (en) | 2001-10-17 | 2006-02-01 | Human Genome Sciences Inc | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP2295468B1 (en) | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
CA2502552C (en) | 2002-10-17 | 2019-02-12 | Genmab A/S | Human monoclonal antibodies against cd20 |
EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2005000901A2 (en) | 2003-05-09 | 2005-01-06 | Duke University | Cd20-specific antibodies and methods of employing same |
AR044388A1 (en) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | CD20 UNION MOLECULES |
EP1651663B1 (en) | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
GT200600031A (en) * | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
AU2006262603B2 (en) | 2005-06-20 | 2011-01-06 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2212432A4 (en) * | 2007-10-22 | 2011-10-19 | Schering Corp | Fully human anti-vegf antibodies and methods of using |
EP3381445B1 (en) * | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
WO2015198451A1 (en) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | Information-processing device, information-processing method, and information-processing program |
-
2009
- 2009-09-09 CA CA2734275A patent/CA2734275A1/en not_active Abandoned
- 2009-09-09 AU AU2009291865A patent/AU2009291865A1/en not_active Abandoned
- 2009-09-09 JP JP2011526940A patent/JP5705115B2/en not_active Expired - Fee Related
- 2009-09-09 CN CN2009801445283A patent/CN102209554A/en active Pending
- 2009-09-09 BR BRPI0918978A patent/BRPI0918978A2/en not_active IP Right Cessation
- 2009-09-09 EP EP12178248.6A patent/EP2684570A1/en not_active Withdrawn
- 2009-09-09 EP EP09792371A patent/EP2334323A2/en not_active Withdrawn
- 2009-09-09 WO PCT/US2009/056365 patent/WO2010030670A2/en active Application Filing
- 2009-09-09 US US12/556,388 patent/US20100068210A1/en not_active Abandoned
- 2009-09-09 KR KR1020117008149A patent/KR20110076918A/en not_active Application Discontinuation
- 2009-09-09 MX MX2011002372A patent/MX2011002372A/en not_active Application Discontinuation
- 2009-09-09 CN CN201310628181.8A patent/CN103599541A/en active Pending
-
2011
- 2011-02-15 IL IL211234A patent/IL211234A0/en unknown
-
2012
- 2012-06-28 US US13/536,584 patent/US20130171162A1/en not_active Abandoned
-
2013
- 2013-10-31 IL IL229180A patent/IL229180A0/en unknown
-
2014
- 2014-12-10 JP JP2014249972A patent/JP2015107973A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1197221A1 (en) * | 1999-03-01 | 2002-04-17 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
EP1700605A2 (en) * | 1999-03-01 | 2006-09-13 | Chugai Seiyaku Kabushiki Kaisha | Lyophilized methionine-containing protein preparations stabilized over long time |
EP1260230A1 (en) * | 2000-02-29 | 2002-11-27 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
Also Published As
Publication number | Publication date |
---|---|
JP2012502102A (en) | 2012-01-26 |
WO2010030670A2 (en) | 2010-03-18 |
US20100068210A1 (en) | 2010-03-18 |
BRPI0918978A2 (en) | 2015-12-01 |
EP2334323A2 (en) | 2011-06-22 |
JP2015107973A (en) | 2015-06-11 |
JP5705115B2 (en) | 2015-04-22 |
AU2009291865A1 (en) | 2010-03-18 |
CA2734275A1 (en) | 2010-03-18 |
EP2684570A1 (en) | 2014-01-15 |
KR20110076918A (en) | 2011-07-06 |
CN102209554A (en) | 2011-10-05 |
CN103599541A (en) | 2014-02-26 |
US20130171162A1 (en) | 2013-07-04 |
MX2011002372A (en) | 2011-04-04 |
IL211234A0 (en) | 2011-04-28 |
IL229180A0 (en) | 2013-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010030670A3 (en) | Compositions and methods for the prevention of oxidative degradation of proteins | |
WO2006051110A3 (en) | Stable formulations of insulinoptropic peptides | |
ZA200705750B (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
IL177030A (en) | Use of d-arg-2',6'-dmt-lys-phe-nh2 for manufacturing a medicament for reducing oxidative damages in a mammal, peptides consisting of the amino acid sequence d-arg-2',6'-dmt-lys-phe-nh2 and compositions comprising them | |
WO2007134279A3 (en) | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
WO2010130832A3 (en) | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions | |
WO2006051103A3 (en) | Stable formulations of peptides | |
NO340679B1 (en) | Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases | |
WO2008030968A3 (en) | Fusion peptide therapeutic compositions | |
IL195030A (en) | Dpp iv inhibitor formulations | |
WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
WO2008021088A3 (en) | Salicylanilides enhance oral delivery of therapeutic peptides | |
WO2009075859A3 (en) | Formulation of insulinotropic peptide conjugates | |
WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
WO2006071840A3 (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
WO2009105774A3 (en) | Amino acid inhibitors of cytochrome p450 | |
WO2007056142A3 (en) | Methods of preventing the serotonin syndrome and compositions for use therefor | |
WO2006089114A3 (en) | Methods and compositions for treating an anthrax toxin mediated condition | |
EP2045253A4 (en) | alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | |
AP3573A (en) | Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
WO2007121124A3 (en) | Hcv inhibitors comprising beta amino acids and their uses | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
WO2009068708A8 (en) | Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof | |
WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980144528.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09792371 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009291865 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 211234 Country of ref document: IL Ref document number: 2734275 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009792371 Country of ref document: EP Ref document number: MX/A/2011/002372 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1522/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009291865 Country of ref document: AU Date of ref document: 20090909 Kind code of ref document: A Ref document number: 2011526940 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117008149 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0918978 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110309 |